143
Views
3
CrossRef citations to date
0
Altmetric
Articles

Outcome of sentinel lymph node biopsy in patients with clinically non-metastatic renal cell carcinoma

ORCID Icon, , , , , , , , , , , , & show all
Pages 411-418 | Received 14 Aug 2018, Accepted 28 Sep 2018, Published online: 11 Dec 2018
 

Abstract

Objective: To investigate the rate of occult SN metastases, oncological outcome, and association of recurrence with the pattern of lymphatic tumour drainage in RCC.

Materials and methods: A pooled RCC sub-group analysis was conducted of secondary endpoints from a published feasibility and a phase II prospective single-arm SN study to investigate oncological outcome. Patients with cT1-3 (<10 cm) cN0M0 RCC of any sub-type were enrolled. After intratumoural injection of Tc99m nanocolloid, pre-operative imaging of SNs with SPECT/CT was followed by (partial) nephrectomy with SN and regional lymph node dissection using a γ-probe. The patients were followed with a risk-adapted surveillance programme. Endpoints of the studies were analysed using Cox proportional hazard models.

Results: Sixty-six RCC patients were included. Two patients (3%, 95% CI =0.5–11%) had occult SN metastases and remained free of disease at 57 and 72 months. Ten patients (15%, 95% CI =7–26%) developed recurrences, and four (6%, 95% CI =2.3–14.5%) had died of disease at a median follow-up of 57 months (IQR =18–72 months). Occurrence of distant metachronous metastases were associated with tumour size (HR =1.39, p = 0.02), pT stage (HR =6.83, p < 0.01 for comparison T1 vs T3/4), Grade 3/4 (HR =8.38, p = 0.05 for comparison 1/2 vs 3/4) and interaortocaval sentinel lymph node location (HR =10.52, p = 0.03 for comparison yes vs no).

Conclusions: The rate of occult metastatic SN is low, but long disease-free survival (DFS) was observed in two patients with occult SN metastases. We hypothesize an interaortocaval lymphatic route in thoracic recurrences. Evaluation of the prognostic and therapeutic role of sentinel lymph node biopsy (SLNB) requires a clinical trial in high-risk RCC.

Acknowledgements

We thank Professor Bradley Leibovich for his valuable comments on lymph node metastases for this work. We gratefully acknowledge Andre Jagt from Antoni van Leeuwenhoek Netherlands Cancer Institute and Camille Laurelli for technical assistance. We would like to thank the European Urological Scholarship Program for financially supporting the research fellowship of Teele Kuusk at Antoni van Leeuwenhoek Hospital/the Netherlands Cancer Institute in Amsterdam, the Netherlands.

Financial disclosure

The authors declare that they have no relevant financial interests.

Disclosure statement

The authors report no conflict of interests.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access
  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart
* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.